Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma

OBJECTIVE: We aimed to evaluate the cost-effectiveness of atezolizumab plus bevacizumab (atezo-bev) versus sorafenib treatment in Taiwan. METHODS: Using sorafenib as the comparator, we developed a partitioned survival model to evaluate the costs and quality-adjusted life year (QALY) of the atezo-bev...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Chien-Yu, Tsai, Yi-Wen, Shiu, Ming-Neng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663301/
https://www.ncbi.nlm.nih.gov/pubmed/38023232
http://dx.doi.org/10.3389/fonc.2023.1264417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663301/
https://www.ncbi.nlm.nih.gov/pubmed/38023232
http://dx.doi.org/10.3389/fonc.2023.1264417

Ejemplares similares